Personalized Neoantigen Vaccines Boost Progress Against Aggressive Cancers 
Cancer Research Catalyst
by Neha J. Pancholi, PhD
5d ago
In 1796, Edward Jenner inoculated a young boy with cowpox to protect him from smallpox, an early example of vaccination.  Fast forward 200+ years: smallpox has been eradicated, and the cowpox virus (now known as vaccinia virus) is being used to develop an entirely different type of vaccine—one that treats cancer.  Unlike preventive vaccines, such as those that protect against COVID-19 and the flu, therapeutic cancer vaccines are designed to treat existing cancers by training the patient’s immune system to recognize and destroy cancer cells.   At the American Association fo ..read more
Visit website
AACR 2024 Plenary Program Kicks Off With New Insights Into Early Cancer Biology  
Cancer Research Catalyst
by Neha J. Pancholi, PhD
5d ago
Seventy percent of cancer-related deaths are from cancer types with no available screening options, underscoring the importance of detecting cancer early when it is more easily treated. The American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, kicked off its plenary program with a session on Discovery Science in Early Cancer Biology and Interception, which was chaired by Daniel De Carvalho, PhD, a professor at University of Toronto and researcher at the Princess Margaret Research Centre.  Daniel De Carvalho, PhD. Photo by © AACR/Scott Morgan 2024. “[Early ..read more
Visit website
The Power of Journalism: The 2024 AACR June L. Biedler Prize Winners
Cancer Research Catalyst
by Andrew Matthius
6d ago
A patient finding hope in a clinical trial for a KRAS-targeted therapy after years of having little progress with other treatments. Exposing how more than 90 countries around the world—many of them low- and middle-income nations—were being sent a poor-quality version of a key chemotherapy drug for the treatment of children with acute lymphoblastic leukemia (ALL). Two breast cancer survivors expressing their frustration with a change in medical insurance codes being the barrier to getting the breast reconstruction surgery they preferred. Examining why 4,310 women in the United States were esti ..read more
Visit website
Accelerated Approval of Cancer Drugs: How Many Verify Clinical Benefit?
Cancer Research Catalyst
by Andrew Matthius
6d ago
Back in 1992, the U.S. Food and Drug Administration (FDA) established its Accelerated Approval Program so drugs that treat serious conditions and fill an unmet need could get to patients faster. This expedited approval is based on surrogate endpoints—such as a laboratory measurement, radiographic image, or physical sign—that the FDA says “is not itself a direct measurement of clinical benefit” but “is reasonably likely to predict clinical benefit.” That’s why these drugs must still be tested in a confirmatory trial that “shows that the drug actually provides a clinical benefit,” before it is ..read more
Visit website
AACR Annual Meeting 2024: Opening Ceremony Highlights a Banner Year
Cancer Research Catalyst
by Andrew Matthius
1w ago
With a record number of more than 23,000 registrants, Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), kicked off the AACR Annual Meeting 2024 with an Opening Ceremony that celebrated a banner year for the organization and the achievements made against cancer overall by many of those in the room. AACR CEO Margaret Foti, PhD, MD (hc) “Progress against cancer continues at a remarkable pace due to unprecedented leaps in our understanding of cancer and in cutting-edge technologies that are allowing us to target this disease with greater ..read more
Visit website
FDA Approvals in Oncology: January-March 2024 
Cancer Research Catalyst
by Cancer Research Catalyst Staff
1w ago
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to the market, while some may have already been approved for other indications; some molecules are first in class, directed against a previously untargeted pathway or acting through a new mechanism, while others may be improved versions of drugs that already exist.      To help our readers keep track of the cancer therapies approved by the U.S. Food and Drug Administration (FDA), understand their impact for patients, and put them in context of the current therape ..read more
Visit website
AACR Annual Meeting 2024: What to Know Before You Go
Cancer Research Catalyst
by Cancer Research Catalyst Staff
1w ago
On April 5, the American Association for Cancer Research (AACR) will welcome what is expected to be a record number of attendees to the San Diego Convention Center for the AACR Annual Meeting 2024. This year features more than 7,200 abstracts—another record for the meeting—along with six plenary sessions, seven focused “Advances” sessions, more than 50 major symposia, four clinical trial plenary sessions, over a dozen forums and special sessions, nearly 300 poster sessions, and much more. To help get the most out of your experience, here are a few important details to remember as you prepare ..read more
Visit website
Education that Enchants—AACR on Campus Goes to Brazil
Cancer Research Catalyst
by AACR Global Affairs
1w ago
Cancer knows no borders, and neither should the latest in cancer research. That’s the idea behind AACR on Campus (AACRoC), a new outreach program designed to advance global collaboration in cancer research. AACRoC offers young investigators at research institutions in low-resource settings across the globe an opportunity to learn from renowned cancer research experts and develop soft skills such as manuscript writing, scientific communication, and network/career development.  In February, AACR on Campus partnered with the Institute of Cancer of São Paulo (ICESP) and University of São Pau ..read more
Visit website
Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
Cancer Research Catalyst
by Cancer Research Catalyst Staff
2w ago
What’s the downside of synergistic drug combinations? Can aggressive cancers be caught early? How does stress impact the gut microbiome?  This month, the editors of the American Association for Cancer Research’s (AACR) 10 peer-reviewed journals have highlighted studies that address these questions and others. Take a look below for the abstract of each featured study, and follow the links to the full articles—freely available for a limited time.  Journal: Blood Cancer Discovery  Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia  C ..read more
Visit website
What Does It Mean to Get Diagnosed with Lynch Syndrome?
Cancer Research Catalyst
by Cancer Research Catalyst Staff
2w ago
Adrienne Skinner, Wenora Johnson, and Alejandro Mirazo each have an increased risk of getting certain cancers due to an inherited condition known as Lynch syndrome. While each of their stories is different, they share commonalities between the lack of awareness that Lynch syndrome existed, the shocking discovery that it did, and the need to stay on top of their health like never before.     “My sister went in for a procedure because she had a bad Pap smear and was in surgery for 14 hours because, during the time that the surgeon had her on the table, the surgeon discovered three dis ..read more
Visit website

Follow Cancer Research Catalyst on FeedSpot

Continue with Google
Continue with Apple
OR